Berta Casar Martínez (IP)

  • IBBTEC. c/ Albert Einstein, 22; 39011 Santander (Spain)
  • berta.casar@unican.es
  • +34 942 206 824
  • Transformation and Metastasis
  • Principal Investigator
  • Cancer
  • Department of Cell & Molecular Signalling

​​

Berta Casar graduated in Biology from the University of León (2001). After a few months of internship at the Hospital Reina Sofía (León, Spain), she joined Piero Crespo's group at CSIC/University of Cantabria (Santander, Spain), where she obtained her PhD studying the regulation of ERK signaling by Mxi2 in cancer in 2006.

Between 2009 and 2012, Berta carried out her postdoctoral studies in Dr. Quigley's group (The Scripps Research Institute, La Jolla, CA, USA), focusing on the study of tumor progression and invasion.

At the end of 2012 she returned to Santander where she leads the Transformation and Metastasis Group. Dr. Casar's research focuses on the search for new therapeutic targets during tumorigenesis and metastasis.

She is the author of more than 30 publications including papers in Cancer Cell, Nature Communications, Molecular Cell, EMBO J, Oncogene and Journal of Cell Biology. Throughout his career he has obtained competitive funding including prestigious grants from the Fundación Ramón Areces, JAE-DOC, and Fundación Francisco Cobos. She has supervised a doctoral thesis, two TFM and three TFG; and has been awarded several national and international prizes. He regularly acts as evaluator for national and international scientific institutions, and as editor and reviewer for several scientific journals. He has been invited to give more than 20 lectures and seminars at congresses, universities and other scientific institutions.​


​​​Transformation and ​Metastasis

IBBTEC's Transformation and Metastasis group investigates signaling pathways involved in alterations during cancer and metastasis.

The ultimate goal of these studies is to identify modulators that may represent new therapeutic targets to curb metastasis and that can be directly translated into effective prevention or treatment strategies.

The group has a multidisciplinary approach and uses chick and mouse embryo models, organoids and 3D cultures, clinical samples and molecular and cellular biology techniques, patient-derived xenografts, to translate basic research into translational oncology and clinically relevant outcomes.

Funding

  • Relevancia funcional de PTPk en la rutaRas-ERK: Implicaciones terapeúticas en melanoma. MICIN(CSIC). 01/01/2017- 31/12/2019. SAF 2015-73364-JIN 
  • Repurposing MAPK inhibitors for the treatment of COVID-19. Proyecto Intramural Especial PIE -CSIC ref 202020E113 15/04/2020-31/12/2023 
  • Bases moleculares de resistencia a quimioterapia en neuroblastoma: identificación de nuevos biomarcadores y dianas terapéuticas. PIE-CSIC. 23/01/2020-present MAPK inhibitors for the treatment of COVID-19. Proyecto Gobierno de Cantabria COVID-19 ORDEN UIC/22/2020. 1/11/2020
  • Mecanismos moleculares que determinan la resistencia a quimioterapia en neuroblastoma. Berta Casar. Proyecto Intramural Especial PIE CSIC 201412 5 9. 1/06/2021- 31/05/2022
  • Definir el mecanismo de activacion de CDCP1 para bloquear metastasis de cancer de mama triple negative. Proyectos de I+D+i. Retos de la Sociedad, del Plan Estatal de Investigación y de Innovación 2017-2020. Referencia PID2020-112760rb-i00. 1/09/2021- 31/8/2024
  • Development of a therapeutic response marker for metastatic melanoma 1/12/2021- 30/11/2023 FERO XXI BFERO2103
  • Investigación preclínica de nuevas terapias dirigidas en Linfoma Cutáneo de Células T. PRECLILINF Proyectos de I+D+i. Retos de la Sociedad, del Plan Estatal de Investigación y de Innovación 2024-2027. 




ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility.

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility.

de la Fuente-Vivas D, Cappitelli V, García-Gómez R, Valero-Díaz S, Amato C, Rodriguéz J, Duro-Sánchez S, von Kriegsheim A, Grusch M, Lozano J, Arribas J, Casar B, Crespo P.

​Mol Oncol. 2025 Feb;19(2):452-473.

View more

The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasis

The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasis

Conde J, Fernández-Pisonero I, Lorenzo-Martín LF, García-Gómez R, Casar B, Crespo P, Bustelo XR.

​Mol Oncol. 2025 Jan;19(1):56-80.​ ​

View more

Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma

Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma

Karagianni F, Piperi C, Valero-Diaz S, Amato C, Vaque JP, Casar B, Papadavid E.

​Cancers (Basel). 2024 Sep 17;16(18):3176.​

View more

DNA damage signalling histone H2AX is required for tumour growth

Contreras L, García-Gaipo L, Casar B, Gandarillas A.

​Cell Death Discov. 2024 Feb 24;10(1):99.​​

View more

Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species

Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species

Martín-Vega A, Ruiz-Peinado L, García-Gómez R, Herrero A, de la Fuente-Vivas D, Parvathaneni S, Caloto R, Morante M, von Kriegsheim A, Bustelo XR, Sacks DB, Casar B, Crespo P.

Sci Adv. 2023 Feb 15;9(7):eadd7969.


View more

PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression

PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression

García-Díaz N, Casar B, Alonso-Alonso R, Quevedo L, Rodríguez M, Ruso-Julve F, Esteve-Codina A, Gut M, Gru AA, González-Vela MC, Gut I, Rodriguez-Peralto JL, Varela I, Ortiz-Romero PL, Piris MA, Vaqué JP

​J Invest Dermatol. 2022 May;142(5):1391-1400.e15.​​

View more

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma

Karagianni F, Piperi C, Casar B, de la Fuente-Vivas D, García-Gómez R, Lampadaki K, Pappa V, Papadavid E.

​Cancers (Basel). 2022 Feb 20;14(4):1070.

View more

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma.

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma.

Colón-Bolea P, García-Gómez R, Casar B

​Biomolecules. 2021 Oct 20;11(11):1554. 

View more

Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells.

Merlos Rodrigo MA, Casar B, Michalkova H, Jimenez Jimenez AM, Heger Z, Adam V.

​Front Oncol. 2021 Sep 1;11:707366.

View more

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer

Moreno, T., Monterde, B., González-Silva, L. et al.

​Oncogene (2021). https://doi.org/10.1038/s41388-021-01748-y

View more

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness.

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness.

Colón-Bolea P, García-Gómez R, Shackleton S, Crespo P, Bustelo XR, Casar B.

​Mol Biol Cell. 2020 Dec 1;31(25):2768-2778. ​​

View more

RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination

RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination

Yaiza García-Ibáñez, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Berta Casar and Piero Crespo

​Cancers (Basel). 2020 Sep 10;12(9):E2588. doi: 10.3390/cancers12092588.

View more

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.

Casar B, Badrock AP, Jiménez I, Arozarena I, Colón-Bolea P, Lorenzo-Martín LF, Barinaga-Rementería I, Barriuso J, Cappitelli V, Donoghue DJ, Bustelo XR, Hurlstone A, Crespo P.

​Nat Commun. 2018 Sep 5;9(1):3595. doi: 10.1038/s41467-018-05941-8.

View more

ERK Signals: Scaffolding Scaffolds?

Casar B, Crespo P. Front Cell Dev Biol. 2016 May 31; 4:49.

[PubMed]

View more

Analysis of Ras/ERK Compartmentalization by Subcellular Fractionation.

Analysis of Ras/ERK Compartmentalization by Subcellular Fractionation.

Agudo-Ibañez L, Crespo P, Casar B.

​Methods Mol Biol. 2017;1487:151-162.

View more

The chick embryo chorioallantoic membrane as an in vivo model to study metastasis.

Crespo P., and Casar B. Bio-protocol Vol 6, Iss 20, Oct 20, 2016 DOI:10.21769/

http://bio-protocol.org/e1962.

View more

Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells.

Herrero A, Casar B, Colón-Bolea P, Agudo-Ibáñez L, Crespo P. Mol Biol Cell. 2016 Apr 20.

[PubMed]

View more

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P.

​Cancer Cell. 2015 Aug 10 [PubMed]

View more

Mxi2 sustains ERK1/2 phosphorylation levels in the nucleus by preventing ERK1/2 binding to phosphatases.

Casar B., Rodríguez J., Gibor G., Seger R., and Crespo P. Biochem. J., 441, 571-578. (2012).

​[pubmed]

View more

ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-independent disruption of Retinoblastoma–LaminA complexes.

Rodríguez J., Calvo F., González J.M., Casar B., Andrés V. and Crespo P. J. Cell Biol. 191, 967-979. (2010). (Editorial en el mismo número; Editorial en Science Sig. 3, ec371 2010; Seleccionado por The Faculty of 1000).

​[pubmed]

View more

Saire Edith Córdova Hernández

View more

David Gámiz Cruz

View more

Carla Martínez Estévez

View more

Celia Pérez Irizábal

View more

Sara Valero Díaz

View more